Literature DB >> 8724818

Insulin-degrading enzyme.

F Authier1, B I Posner, J J Bergeron.   

Abstract

The authors review recent research on an enzyme hypothesized to play a major role in the degradation of insulin. After binding to its receptor on the cell surface, insulin is internalized by receptor-mediated endocytosis and degraded within components of the endosomal apparatus. Degradation of insulin is important in the termination of signaling and clearance of the circulating hormone. It has been proposed that insulin-degrading enzyme (IDE), an evolutionarily conserved, neutral thiol-metalloendopeptidase, plays a crucial role in the degradation of internalized insulin in many types of cells. Despite the substantial evidence supporting the importance of IDE in cellular insulin degradation, there is controversy over its mode and site of action, mainly because of its cytosolic location. Its physiological location in cells has recently been elucidated through subcellular fractionation of liver parenchyma and through immunofluorescence microscopy of stably transfected Chinese hamster ovary cells that overexpress IDE. These experiments have excluded the presence of the enzyme in endosomes and have defined a peroxisomal location, consistent with the presence of a peroxisomal targeting sequence at the carboxyl terminus of the protein. Recently, researchers have demonstrated the functional significance of peroxisome-associated IDE (type I peroxisomal enzyme) in degrading cleaved leader peptides of peroxisomal proteins targeted by the type II motif. IDE is the first cloned and characterized proteinase to be localized to peroxisomes. Moreover, IDE appears to be a member of a newly identified superfamily of metalloendopeptidases that has an HXXEH active-site motif. Although fundamental questions concerning the biological role of IDE remain, its high degree of evolutionary conservation suggests that it must have important functions and multifaceted biological significance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8724818

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  50 in total

1.  Disorders of glucose metabolism: post mortem analyses in forensic cases--part II.

Authors:  Frank Musshoff; Cornelius Hess; Burkhard Madea
Journal:  Int J Legal Med       Date:  2010-10-07       Impact factor: 2.686

Review 2.  The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  G Stennis Watson; Suzanne Craft
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

3.  Modulation of neuronal pentraxin 1 expression in rat pancreatic β-cells submitted to chronic glucotoxic stress.

Authors:  Domitille Schvartz; Yohann Couté; Yannick Brunner; Claes B Wollheim; Jean-Charles Sanchez
Journal:  Mol Cell Proteomics       Date:  2012-03-16       Impact factor: 5.911

4.  Genetic factors moderate everyday physical activity effects on executive functions in aging: Evidence from the Victoria Longitudinal Study.

Authors:  Sherilyn Thibeau; G Peggy McFall; Sandra A Wiebe; Kaarin J Anstey; Roger A Dixon
Journal:  Neuropsychology       Date:  2016-01       Impact factor: 3.295

Review 5.  Hepatic Insulin Clearance: Mechanism and Physiology.

Authors:  Sonia M Najjar; Germán Perdomo
Journal:  Physiology (Bethesda)       Date:  2019-05-01

6.  A common genetic system for functional studies of pitrilysin and related M16A proteases.

Authors:  Benjamin J Alper; Tatyana E Nienow; Walter K Schmidt
Journal:  Biochem J       Date:  2006-08-15       Impact factor: 3.857

7.  Loss of renal SNX5 results in impaired IDE activity and insulin resistance in mice.

Authors:  Fengmin Li; Jian Yang; Van Anthony M Villar; Laureano D Asico; Xiaobo Ma; Ines Armando; Hironobu Sanada; Minoru Yoneda; Robin A Felder; Pedro A Jose; Xiaoyan Wang
Journal:  Diabetologia       Date:  2017-10-28       Impact factor: 10.122

8.  Expression of metalloprotease insulin-degrading enzyme insulysin in normal and malignant human tissues.

Authors:  Christina Yfanti; Karin Mengele; Apostolos Gkazepis; Gregor Weirich; Cecylia Giersig; Wen-Liang Kuo; Wei-Jen Tang; Marsha Rosner; Manfred Schmitt
Journal:  Int J Mol Med       Date:  2008-10       Impact factor: 4.101

9.  17β-Estradiol regulates insulin-degrading enzyme expression via an ERβ/PI3-K pathway in hippocampus: relevance to Alzheimer's prevention.

Authors:  Liqin Zhao; Jia Yao; Zisu Mao; Shuhua Chen; Yan Wang; Roberta Diaz Brinton
Journal:  Neurobiol Aging       Date:  2010-01-06       Impact factor: 4.673

Review 10.  Deregulation of brain insulin signaling in Alzheimer's disease.

Authors:  Yanxing Chen; Yanqiu Deng; Baorong Zhang; Cheng-Xin Gong
Journal:  Neurosci Bull       Date:  2014-03-20       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.